DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Metoclopramide for Migraine: A Dose Finding Study

Information source: Montefiore Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine

Intervention: metoclopramide (Drug); metoclopramide (Drug); metoclopramide (Drug); Diphenhydramine 25mg (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Montefiore Medical Center

Official(s) and/or principal investigator(s):
Benjamin W. Friedman, MD, MS, Principal Investigator, Affiliation: Montefiore Medical Center


Metoclopramide is an effective intravenous treatment for acute migraine attacks, but we do not know the best dose to administer. This study compares three different doses of metoclorpamide.

Clinical Details

Official title: Metoclopramide for Acute Migraine: A Dose Finding Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Pain Intensity Score

Detailed description: Patients with acute migraine attacks are eligible for enrollment if they present to the emergency department of Montefiore Medical Center. Pain scores are assessed at baseline and every 30 minutes for two hours, and then again by telephone 48 hours after discharge


Minimum age: 18 Years. Maximum age: 69 Years. Gender(s): Both.


Inclusion Criteria:

- acute migraine

Exclusion Criteria:

- secondary cause of headache

- lumbar puncture

- allergy or intolerance to study medication

Locations and Contacts

Montefiore Medical Center, Bronx, New York 10467, United States
Additional Information

Starting date: April 2008
Last updated: November 28, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017